



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/849,602	05/04/2001	Yao-Tseng Chen	L0461/7105(JRV/MXA)	8884

23628 7590 04/15/2003

WOLF GREENFIELD & SACKS, PC
FEDERAL RESERVE PLAZA
600 ATLANTIC AVENUE
BOSTON, MA 02210-2211

EXAMINER

LY, CHEYNE D

ART UNIT	PAPER NUMBER
----------	--------------

1631

DATE MAILED: 04/15/2003

12

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 09/849,602	Applicant(s) CHEN ET AL.	
	Examiner Cheyne D Ly	Art Unit 1631	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on March 24, 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-6, 15, 16, 20, 47, 48, 51, 56, 57, 60, 86-89, 90, and 98 is/are pending in the application.
- 4a) Of the above claim(s) 6, 20, 51, 56, 57, 60, and 90 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-5, 15, 16, 47, 48, 86-89, and 98 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-6, 15, 16, 20, 47, 48, 51, 56, 57, 60, 86-89, 90, and 98 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on _____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input checked="" type="checkbox"/> Interview Summary (PTO-413) Paper No(s). <u>12</u> . |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ | 6) <input type="checkbox"/> Other: |

Art Unit: 1631

DETAILED ACTION

1. Applicant's election without traversal of Group I, claims 1-5, 15, 16, 47, 48, 86-89, and 98, SEQ ID NOs: 1 and 5 encoding polypeptides, SEQ ID NOs: 16 and 20 on Examiner Interview Summary, Paper No.12, filed April, 2003, is acknowledged.

2. It is noted that traversal to the sequence election requirement in Paper 11, filed February 21, 2002, has been considered. Therefore, Examiner has revised the Selection Election Requirement to read:

3. Each Group detailed in Written Restriction office action Paper No. 9, mailed January 27, 2003, reads on patentably distinct sequences. Each sequence is patentably distinct because they are unrelated sequences, and a further restriction is applied to each Group. For an elected Group drawn to amino acid/polypeptide sequences, the Applicants must further elect a panel consisting of polypeptides represented by SEQ ID NOs: 16-30. For an elected Group drawn to nucleic acid sequences, the Applicants must further elect a panel consisting of sequences represented by SEQ ID NOs: 1-15. (See MPEP § 803.04).

MPEP § 803.04 states:

Nucleotides sequences encoding different proteins are structurally distinct chemical compounds and are unrelated to one another. These sequences are thus deemed to normally constitute independent and distinct inventions with the meaning of 35 U.S.C. 121. Absent evidence to the contrary, each such nucleotide sequence is presumed to represent an independent and distinct invention, subject to a restriction requirement pursuant to 35 U.S.C. 121 and 37 CFR 1.141 et seq. Examination will be restricted to

Art Unit: 1631

only the elected sequence. It is additionally noted that this sequence election requirement is a restriction and not a specie election requirement.

4. The requirement is still deemed proper and is therefore made FINAL.
5. Claims 1-5, 15, 16, 47, 48, 86-89, and 98 are examined on the merits.

Information Disclosure Statement

6. The information disclosure statement, Paper No. 10, filed February 10, 2003, fails to comply with 37 CFR 1.98(a)(2), which requires a legible copy of each U.S. and foreign patent; each publication or that portion which caused it to be listed; and all other information or that portion which caused it to be listed. It is noted that this instant application file lacks the documents listed on the said information disclosure statement. It has been placed in the application file, but the information referred to therein has not been considered.

Claim Rejections - 35 USC § 112

7. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

8. Claims 4, 5, 15, 47, 48, 88, and 98 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

9. Specific to claims 4 and 88, the phrase "antigen-binding fragments thereof" cause the claim to be vague and indefinite. It is unclear as to what Applicants mean by fragments thereof. Is it a nucleic acid or polypeptide? Clarification of the metes and bounds of the instant claims is required.

Art Unit: 1631

10. Specific to claim 5, the method further comprising of contacting the biological sample with colon cancer-associated polypeptide other than those encoded by...selected from the group consisting of SEQ ID NOs: 1-15 is vague and indefinite. It is unclear as to which colon cancer-associated polypeptide is being used to contact the biological sample. Is it any colon cancer-associated polypeptide that is encoded by a sequence represented SEQ ID NOs:1-15, but, have not been selected by the said method? Or is it any colon cancer-associated polypeptide that is not encoded by any sequence represented SEQ ID NOs: 1-15? Clarification of the metes and bounds of the instant claim is required.

11. Specific to claims 15 and 98, the preamble of the claims recites a method for determining onset, progression, or regression, of colon cancer in a subject. However, these claims lack any time dependency limitations, which are required to accomplish the intended of the claims. It is unclear how the intended goal of the claims is achieved without the active steps of requiring a time dependency limitation. It is noted that the specification on pages 28-29 contains sampling time statements, such as “subsequent sample” or “subject’s samples over time”, however; such time requirements are not the claims. Clarification of the metes and bounds of the instant claims is required. Claim 16 is rejected for being dependent from claim 15.

12. Specific to claim 47, line 4, the phrase “one or more control antigens” causes the claim to be vague and indefinite. It is unclear what an antigen is controlling in this kit. Is an antigen controlling the binding interaction between a colon-cancer associated polypeptide and a biological agent or the diagnosis of colon cancer? Clarification of the metes and bounds of the instant claim is required. Claim 48 is rejected for being dependent from claim 47.

Art Unit: 1631

13. Specific to claims 15 and 98, the active steps for determining onset, progression, or regression, of cancer in a subject causes the claim to be vague and indefinite. Line 3 is directed to the step of "obtaining from a subject a first biological sample" for analysis and line 9 is directed to the step of "obtaining from a subject a second biological sample" for analysis. One interpretation of these two steps is that samples are obtained from different subjects. How is the "determining onset, progression, or regression, of cancer" achieved when one maybe comparing samples from different subjects? Applicant can resolve this issue by particularly pointing out that the samples are obtained from the same subject. Clarification of the metes and bounds of the instant claim is required. Claim 16 is reject for being dependent from claim 15.

LACK OF UTILITY UNDER 35 U.S.C. § 101:

14. The pending claims have been reviewed in light of the Utility Examination Guidelines and Guidelines for Examination of Patent Applications under 35 U.S.C. 112, first paragraph, "Written Description" Requirement, Federal Register, Vol. 66, No. 4, pages 1092-1111, Friday, January 5, 2001.

15. The examiner is using the following definitions in evaluating the claims for utility.

"Specific" - A utility that is *specific* to the subject matter claimed. This contrasts with a *general* utility that would be applicable to the broad class of the invention.

"Substantial" - A utility that defines a "real world" use. Utilities that require or constitute carrying out further research to identify or reasonably confirm a "real world" context of use are not substantial utilities.

"Credible" - Credibility is assessed from the perspective of one of ordinary skill in the art in view of the disclosure and any other evidence of record that is probative of the applicant's assertions. That is, the assertion is an inherently unbelievable undertaking or involves implausible scientific principles.

Art Unit: 1631

"Well-established" - a specific, substantial, and credible utility which is well known, immediately apparent, or implied by the specification's disclosure of the properties of a material, alone or taken with the knowledge of one skilled in the art.

35 U.S.C. § 101 reads as follows:

"Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title".

16. Claims 1-5, 15, 16, 47, 48, 86-89 and 98 are rejected under 35 U.S.C. § 101 because the claimed invention lacks patentable utility due to its not being supported by a specific, substantial, and credible utility or, in the alternative, a well-established utility.

17. The critical limitations of claims 1-5, 15, 16, 47, 48, 86-89 and 98 are nucleic acids, SEQ ID NOs: 1 and 5 encoding polypeptides, SEQ ID NOs: 16 and 20.

18. The claimed polynucleotides are not supported by a substantial utility because no substantial utility has been established for the claimed subject matter. For example, a nucleic acid may be utilized to obtain a protein. The protein could then be used in conducting research to functionally characterize the protein. A starting material that can only be used to produce a final product does not have substantial asserted utility in those instances where the final product is not supported by a specific and substantial utility. In this case, the protein produced as a final product resulting from processes involving the nucleic acid does not have asserted or identified specific and substantial utilities. Identifying and studying the properties of a protein itself or the mechanisms in which the protein is involved, such as the cancer-associated polypeptide encoded by SEQ ID NOs:1 and 5, does not define a "real world" context for use. Similarly, the other listed utilities and asserted utilities as summarized in the instant specification (Pages 23-24) are not substantial due to being generic in nature and applicable to many such compounds.

Art Unit: 1631

19. It is acknowledged that Applicants disclose colon cancer-associated polypeptides, which have been identified through SEREX screening of patients with cancer (Page 13, lines 10 and 11). As disclosed in the Sahin et al. reference cited in this instant application, the process of identifying antigen is through sequence analysis. "Sequence alignments were performed with DNAIS (Pharmacia) and BLAST software on European Molecular Biology Laboratory (EMBL) and GenBank databases (Sahin et al., Page 11810, column 2, lines 41-44 to Page 11811, column 1, lines 1-7). The colon cancer-associated polypeptides of this instant application have been identified through SEREX screening of patients with cancer. The SEREX method requires antigen to be identified via sequence comparisons with either the EMBL or GenBank databases. Absent factual evidence, one skilled in the art would have reason to doubt that sequence similarity alone would reasonably support the assertion that the biological activity of the claimed subject matter would be the same as that of the similar sequence.

20. Furthermore, it is unclear whether the similar sequence identified in the prior art (EMBL or GenBank databases) has actually been tested for the biological activity or whether this also is an asserted biological activity based upon sequence similarity to yet a different sequence. Note that it would have been well known in the art that sequence similarity does not reliably correlate to structural similarity and that structural similarity does not reliably result in similar or identical biological activities. For example, it would have been well known that even a single nucleotide or amino acid change or mutation can destroy the function of the biomolecule in many instances, albeit not in all cases. In the absence of factual evidence characterizing the structural and functional components of the biomolecule, the effects of these changes are largely unpredictable as to which ones will have a significant effect and which ones will be silent mutations having no

Art Unit: 1631

effect. Several publications document the unpredictability of the relationship between sequence, structure, and function, although it is acknowledged that certain specific sequences have been found to be conserved in biomolecules having related function following a significant amount of further research. See Lopez et al. (Molecular Biology, 32:881-891,1999); Attwood (Science, 290:471-473, 2000); Gerhold et al. (BioEssays, 18(12):973-981, 1996); Wells et al. (Journal of Leukocyte Biology, 61(5):545-550, 1997); and Russell et al. (Journal of Molecular Biology, 244:332-350, 1994). However, this level of factual evidence is absent here.

Claims Rejected Under U.S.C. § 112, First Paragraph

21. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

LACK OF ENABLEMENT

22. Claims 1-5, 15, 16, 47, 48, 86-89 and 98 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention.

23. Factors to be considered in determining whether a disclosure would require undue experimentation have been summarized in Ex parte Forman, 230 USPQ 546 (BPAI 1986) and reiterated by the Court of Appeals in In re Wands, 8 USPQ2d 1400 at 1404 (CAFC 1988). The factors to be considered in determining whether undue experimentation is required include: (1) the quantity of experimentation necessary, (2) the amount or direction presented, (3) the presence

Art Unit: 1631

or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art, and (8) the breadth of the claims. The Board also stated that although the level of skill in molecular biology is high, the results of experiments in genetic engineering are unpredictable. While all of these factors are considered, a sufficient amount for a prima facie case is discussed below.

24. The claimed invention is not supported by a specific and substantial utility for the reasons set forth above (refer to 35 U.S.C. § 101 rejection), one skilled in the art would not know how to use the claimed invention without undue experimentation.

LACK OF WRITTEN DESCRIPTION

25. Claim 5 is rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

26. The specification discloses SEQ ID NOs: 1 and 5 encoding polypeptides, SEQ ID NOs: 16 and 20. Claim 5 is directed to encompass colon cancer-associated polypeptides other than those encoded by nucleic acid molecules SEQ ID NOs: 1 and 5 (See Paragraph 9 of this instant application). None of these sequences or molecules meet the written description provision of 35 USC 112, first paragraph. The specification provides insufficient written description to support the genus encompassed by the claim.

Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purposes of the 'written description' inquiry, whatever is now claimed." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116.)

27. With the exception of SEQ ID NOs: 1 and 5 which encode for polypeptides SEQ ID NOs: 16 and 20, the skilled artisan cannot envision the detailed chemical structure of the encompassed polynucleotides and/or proteins, regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. See *Fiers v. Revel*, 25 USPQ2d 1601, 1606 (CAFC 1993) and *Amgen Inc. V. Chugai Pharmaceutical Co. Ltd.*, 18 USPQ2d 1016. In *Fiddes v. Baird*, 30 USPQ2d 1481, 1483, claims directed to mammalian FGF's were found unpatentable due to lack of written description for the broad class. The specification provided only the bovine sequence.

University of California v. Eli Lilly and Co., 43 USPQ2d 1398, 1404, 1405 held that: ...To fulfill the written description requirement, a patent specification must describe an invention and do so in sufficient detail that one skilled in the art can clearly conclude that "the inventor invented the claimed invention." *Lockwood v. American Airlines, Inc.* , 107 F.3d 1565, 1572, 41 USPQ2d 1961, 1966 (1997); In *re Gosteli* , 872 F.2d 1008, 1012, 10 USPQ2d 1614, 1618 (Fed. Cir. 1989) (" [T]he description must clearly allow persons of ordinary skill in the art to recognize that [the inventor] invented what is claimed."). Thus, an applicant complies with the written description requirement "by describing the invention, with all its claimed limitations, not that which makes it obvious," and by using "such descriptive means as words, structures, figures, diagrams, formulas, etc., that set forth the claimed invention." *Lockwood* , 107 F.3d at 1572, 41 USPQ2d at 1966.

28. Therefore, only SEQ ID NO: 1 and 5 which encode for polypeptides SEQ ID NOs: 16 and 20 but not the full breadth of the claim 5 meets the written description provision of 35 USC 112, first paragraph. The species specifically disclosed are not representative of the genus because the genus is highly variant. Applicant is reminded that *Vas-Cath* makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. (See page 1115.)

Art Unit: 1631

CONCLUSION

29. NO CLAIM IS ALLOWED.

30. Papers related to this application may be submitted to Technical Center 1600 by facsimile transmission. Papers should be faxed to Technical Center 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform with the notices published in the Official Gazette, 1096 OG 30 (November 15, 1988), 1156 OG 61 (November 16, 1993), and 1157 OG 94 (December 28, 1993) (see 37 CFR § 1.6(d)). The CM1 Fax Center number is either (703) 308-4242 or (703) 305-3014.

31. Any inquiry concerning this communication or earlier communications from the examiner should be directed to C. Dune Ly, whose telephone number is (703) 308-3880. The examiner can normally be reached on Monday-Friday from 8 A.M. to 4 P.M.

32. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Woodward, Ph.D., can be reached on (703) 308-4028.

33. Any inquiry of a general nature or relating to the status of this application should be directed to Legal Instruments Examiner, Tina Plunkett, whose telephone number is (703) 305-3524 or to the Technical Center receptionist whose telephone number is (703) 308-0196.

C. Dune Ly
4/12/03


ARDIN H. MARSCHEL
PRIMARY EXAMINER